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The European Clinical Trials Directive (EU 2001; 2001/
20/EC) was introduced to improve the efﬁciency of
commercial and academic clinical trials. Concerns have
been raised by interested organizations and institutions
regarding the potential for negative impact of the
Directive on non-commercial European clinical research.
Interested researchers within the European Group for
Blood and Marrow Transplantation (EBMT) were
surveyed to determine whether researcher experiences
conﬁrmed this view. Following a pilot study, an internet-
based questionnaire was distributed to individuals in key
research positions in the European haemopoietic SCT
community. Seventy-one usable questionnaires were
returned from participants in different EU member
states. The results indicate that the perceived impact
of the European Clinical Trials Directive has been
negative, at least in the research areas of interest to
the EBMT.
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Introduction
The European Clinical Trials Directive (EU 2001; 2001/20/
EC) was introduced on 1 May 2004 to simplify and
harmonize the administrative procedures governing com-
mercial and academic clinical trials. Concerns have been
raised by interested organizations and institutions regard-
ing the potential for negative impact of the Directive on
non-commercial European clinical research.
1–6 These have
been supported by empirical investigation.
7 The impact
may not be negative in all EU member states for all types of
clinical trials.
8,9 The predominant view is that the net
impact of the Directive has been to increase the adminis-
trative burden associated with the competent authority and
ethical clearances, in particular for multinational trials.
10
The aim of the research presented here was to examine
researcher concerns and perceptions regarding the impact
of the Directive on academic clinical trials in the area of
haematopoietic SCT.
Materials and methods
A pilot questionnaire (All questionnaires are available from
the corresponding author upon request.) was designed and
distributed electronically to active researchers within the
European Group for Blood and Marrow Transplantation
(EBMT). This aimed to explore researcher concerns
about conducting clinical trials in the area of SCT, post-
implementation of the European Clinical Trials Directive.
Respondents were asked to provide information about
their professional responsibilities associated with prospec-
tive clinical trials, including drug trials (job description,
institution, country and experience with single-centre,
multicentre national and multicentre international pros-
pective clinical trials relating to SCT, and institutional
activities related to different types of prospective clinical
trials). Information was then provided regarding the date of
implementation of the European Clinical Trials Directive in
different EU member states. Respondents were asked
whether they thought the numbers of academic and
pharmaceutical clinical trials (single-centre, multicentre
national and multicentre international) being conducted
in their country and by their own institutions had
been inﬂuenced by the implementation of the Directive.
Respondents were also asked the reasons why they thought
a decline in the numbers of trials had occurred where
relevant.
Forty-one respondents returned the pilot questionnaire.
The results indicated that the majority of respondents
perceived the impact of the Directive to be negative (75%),
although a minority reported that it had made no difference
or had a positive effect on the implementation of
prospective clinical trials. Nearly all respondents reported
being involved, at a reasonably senior level, in academic
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www.nature.com/bmtclinical trials. The higher number of respondents from
certain EU member states (for example, Germany)
may have reﬂected the differential perception of problems
and concerns in these states in particular (Table 1). The
results of the pilot questionnaire were used to develop
the main study questionnaire. The questionnaire used the
results of the qualitative analysis of the pilot study
results to formulate closed questions, focused on (1)
researcher perceptions of the potential problems that have
arisen following the implementation of the European
Clinical Trials Directive (Table 2), and (2) their priorities
for speciﬁc changes that could improve the implementation
of clinical trials in areas of relevance to the EBMT
(Table 3).
Cascade methodology was applied to ensure equal
distribution of responses across EU member states.
Respondents were recruited via the Chairs of the 11 EMBT
Working Parties. This enabled the opinions of individuals
in key research positions in the European haemopoietic
SCT community to be surveyed.
Results
Seventy-one usable questionnaires were returned. As
before, respondents provided information about their
professional responsibilities. All respondents were senior
researchers or principal investigators who were actively
involved in clinical trials in the area of haemopoietic SCT
and were located across different EU member states
(Table 1). In all, 86% had been involved in multicentre
national trials at a senior level. In line with the results of the
pilot study, 70% of respondents indicated that they
perceived the overall impact of the Directive to be negative,
20% positive, 3% reported no change and the remainder
expressed no opinion. Respondents were asked whether
they ‘believed that time to Ethics Committee/Competent
Authority approval is longer or shorter since the imple-
mentation of the Clinical Trials Directive’, and, if they
replied ‘longer’, to indicate whether this was attributable to
increased pre-submission administration, increased post-
submission committee delays or other factors. Generally
respondents (63.4%) perceived that time to approval was
longer. Of these, 93% attributed this to pre-submission
administration delays and 69% to post-submission delays
(some participants indicated both as relevant). Other
delaying factors were indicated as important by 76% of
this subsample.
In response to the question ‘do you consider it more
difﬁcult for institutions in your country to become involved
in academic prospective clinical trials since the implemen-
tation of the Clinical Trials Directive’, 86% of the
participants reported that it was more difﬁcult to become
involved in single-centre prospective clinical trials, 82% in
multicentre clinical trials and 86% in international multi-
centre clinical trials.
A series of statements regarding researcher perspectives
on the impact of the European Clinical Trials Directive
were developed from the pilot study. These statements are
included as they appeared in the questionnaire in Table 2.
Participants were asked to rate the extent to which
Table 1 Response rates and distribution across EU member states
Country Number of participants
Austria 2
Belgium 4
Denmark 1
Finland 2
France 9
Germany 12
Greece 1
Hungary 2
Italy 7
Netherlands 4
Norway 1
Poland 3
Spain 3
Sweden 6
Turkey 4
UK 9
No response 1
Table 2 Rating by the participants of the extent to which they agreed or disagreed with statements regarding the impact of the European
Clinical Trials Directive, developed from the pilot study
Researcher agreement or disagreement with statements regarding the impact of the European Clinical Trials Directive Mean rating (s.e.) s.e.
Increased volume of paperwork 1.11
a (0.04)
Increased demands for study conduct (such as monitoring or audit) 1.29
ab (0.07)
Increased running costs associated with the trial 1.43
ac (0.90)
Increased legal requirements in general 1.50
bc (0.70)
Increased approval costs 1.55
bc (0.20)
Increased costs of insurance/indemnity 1.63
bc (0.10)
Delays in institutional approval (such as research and development or approval from the directorate) 1.65
bc (0.11)
Increased liability 1.67
c (0.10)
Increased number of regulatory authorities required to approve trial 1.68
c (0.11)
Increased requirements for ethics approval 1.72
c (0.12)
Committees requiring use of their own forms in addition to national or internationally agreed forms 1.94
c (0.14)
Practical problems with ofﬁcial forms (e.g. form cannot be saved) 2.00
cd (0.14)
Lack of harmonization between forms used by committees at national level 2.27
d (0.16)
Lack of harmonization of forms used by different committees at local level 2.33
d (0.16)
The statements are included in the above table. A lower average score indicates greater average respondent agreement with each statement. Superscript
characters are used to indicate which means are signiﬁcantly different from each other (as assessed by the Tukey post-hoc test for pairwise differences). Two
means sharing a superscript character implies that they are not signiﬁcantly different from each other. Otherwise they are.
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Bone Marrow Transplantationthey agreed or disagreed with each statement (5-point
rating scale, anchored by 1¼‘agree strongly’ and 2¼
‘disagree strongly’, midpoint of ‘neither agree nor disagree’,
and a ‘no opinion’ option). Application of a general
linear model repeated-measures procedure tested for
the main effects of trial type (single-centre, multicentre
national and multicentre international), type of concern
and potential interactions between these. For all types
of trials, the average ratings were below the midpoint of
the scale, indicating that participants tended to evaluate
negatively the impact of the European Clinical
Trials Directive across all of the items. Differences did
not (quite) reach the signiﬁcance for trial type
(F(2,41)¼3.7, P¼0.06).
A signiﬁcant effect attributable to type of concern was
observed (F(13,30)¼5.6, Po0.001). Signiﬁcant pairwise
differences (Tukey’s post-hoc test) between different types
of concern are summarized in Table 2. The greatest concern
was associated with the increased volume of paperwork,
increased demands associated with running the trial (mon-
itoring or audit, or legal requirements), or increased costs for
insurance or ethical approval. The signiﬁcant interaction
between type of concern and trial type (F(26,17)¼2.39,
Po0.05, Figure 1) indicated that greater concerns were
expressed for multicentre international trials regarding
increased insurance costs, delays in institutional approval
and increased liability. Concerns about increased running
costs and increased legal requirements were not so great.
The lower levels of concern about the potential increase in
regulatory approvals may reﬂect that, in most countries,
there is already an obligation pre-Directive to gain
approval.
Finally, respondents rated potential changes that might
be implemented to facilitate national single-centre, national
multicentre or international multicentre trials. The different
items, derived from the pilot study, are reproduced in
Table 3. As before, a general linear model repeated-
measures procedure was applied. A signiﬁcant main effect
attributable to type of change was observed (F(16,
44)¼6.14, Po0.001). Signiﬁcant differences are summar-
ized in Table 3. Note that all of the mean scores had values
less than the midpoint of the scale (3), indicating, on
average, agreement with all the changes. Reduction in
administrative burden, harmonization of documents required
for approval, and increased access to public funding for
clinical trials and translational research were priority
changes for respondents.
Discussion
The results indicate that the perceived impact of the
European Clinical Trials Directive has been negative,
at least in the research areas of interest to EBMT. The
results of the pilot and main studies suggest similar
interpretation in this regard, despite the potential
self-selection bias for respondents included in the pilot
study. In terms of identifying potential changes that
would remedy the situation, prioritization was given to
the need to reduce the administrative burden associated
with running academic clinical trials. As part of this, the
need to harmonize documentation associated with the
application process for trial approval and monitoring
was identiﬁed. Increased insurance costs, delays in institu-
tional approval and increased liability were particularly
problematic for multicentre international trials. The crea-
tion of a single European Competent Authority was not
rated as being as important as some of the other potential
changes.
To conclude, the results support the impression provided
by much of the literature that the European Clinical Trials
Directive has increased the (perceived) administrative
burden on researchers, and introduced additional barriers
and bottlenecks into the research process. This may be
Table 3 Mean scores for priorities for changes in the European Clinical Trials Directive
Type of change required post-implementation of the European Clinical Trials Directive Mean rating s.e.
Reduction in administrative burden 1.20
a 0.16
Harmonization of documents required for approval 1.35
ab 0.22
Increased public funding for prospective clinical trials 1.42
abc 0.18
More readily available support from the EU for translational clinical research 1.50
abc 0.19
Provision of ethical and regulatory approval free of charge for academic institutions 1.53
bc 0.20
Centralization of documents required for approval 1.55
bcd 0.17
National government or EU subsidization of insurance costs 1.60
bcde 0.21
Permitting co-sponsorship of academic prospective clinical trials 1.60
bcdef 0.20
Improved deﬁnition of interventional versus non-interventional clinical trial 1.67
bcdefg 0.21
Clearer differentiation between ‘commercial’ and non-commercial clinical trial 1.72
bcdefgh 0.22
Improved deﬁnition of substantial versus non-substantial protocol amendment 1.73
cdefghij 0,.22
Reduction in the degree of monitoring required for investigator-led trials 1.75
cdefghijk 0.23
Implementation of a true single opinion in a member state 1.82
cdefghijkl 0.24
Improved deﬁnition of an interventional medicinal product (IMP) 1.85
cdefghijkl 0.24
EU or nationally funded local training on administrative requirements of the directive 1.88
cdefghiklm 0.24
Creation of a single Competent Authority for all EU member states 1.90
cdefghiklm 0.24
Permitting industry to use data from ‘non-commercial’ clinical trials 2.35
m 0.30
Participants were asked to rate the extent to which they agreed or disagreed that changes associated with the implementation of the European Clinical trials
directive should be prioritized. A lower average score indicates greater average respondent agreement that the change should be prioritized. Superscript
characters are used to indicate which means are signiﬁcantly different from each other (as assessed by Tukey’s post-hoc test for pairwise differences). Two
means share a superscript character implies that they are not signiﬁcantly different from each other. Otherwise they are.
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Bone Marrow Transplantationattributable to the process by which each member state
incorporated the Directive into national legislation, thereby
introducing important differences in interpretation. Policy
changes are required, speciﬁcally aimed at facilitating
clinical trials by promoting harmonization, reducing
administrative burdens, and streamlining the regulatory
and approval process.
The CLINT project partners met to share the ﬁndings
with ICREL (Impact on Clinical Research of European
Legislation, a 1-year project funded by FP7 to measure
change in the performance of clinical trials in Europe
between 2003 and 2007), ECRIN (European Clinical
Research Infrastructures Network) and ELN (The Eur-
opean Leukaemia Network). The meeting also took into
account the ﬁndings of the European Science Foundation
‘Forward Look’.
11 A series of stakeholder workshops (also
involving EFGCP, the European Forum for Good Clinical
Practice.) have explored issues relevant to clinical research
in Europe, and will deliver recommendations through a
ﬁnal stakeholder conference in mid-2010, speciﬁcally a set
of concrete and actionable recommendations relevant to
the formal review of the Directive, which is scheduled
in 2010.
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